Search

The article compares the mortality of bullous pemphigoid (BP) in Europe and the US. The reported mortality of BP is much greater in Europe than in the U.S. Mortality 1 year after initiation of therapy ranges from 19% to 41% in Europe but is only 6%12% in the U.S. Studies in the U.S. are generally smaller than those conducted in Europe. However, the consistency of the reports, i.e., mortality in all European studies, is higher than in all U.S. studies, and the clear nature of the end-point (death) suggest the reported differences between European and U.S. studies are real.

This article presents information on a research workshop sponsored by the National Institute of Arthritis and Musculosketeal and Skin Diseases and the National Alopecia Areata Foundation on alopecia areata, a common hair follicle disease. This landmark workshop was held during October 25-26, 1990 in Lister Hill auditorium at the National Institutes of Health, Bethesda, Maryland. It brought together basic and clinical scientists from dermatology, immunology, pathology, biology, biochemistry, pharmacology, genetics and anatomy.